Open6.000 | Close- |
Vol / Avg.85.796K / 17.185K | Mkt Cap866.035M |
Day Range6.000 - 7.431 | 52 Wk Range7.600 - 20.000 |
Curis Stock (NASDAQ: CRIS) stock price, news, charts, stock research, profile.
Open6.000 | Close- |
Vol / Avg.85.796K / 17.185K | Mkt Cap866.035M |
Day Range6.000 - 7.431 | 52 Wk Range7.600 - 20.000 |
Q3 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED) | ||||||
REV |
Q2 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.120 | -0.120 | 0.0000 | ||||
REV | 2.570M | 2.197M | -373.000K |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|---|---|---|---|---|---|---|
2023-09-25 | HC Wainwright & Co. | Edward White | Reiterates | BuyBuy | Maintains | - | 6.00 |
2023-09-07 | Cantor Fitzgerald | Alethia Young | Reiterates | OverweightOverweight | Maintains | - | 3.00 |
2023-08-04 | HC Wainwright & Co. | Edward White | Reiterates | BuyBuy | Maintains | - | 6.00 |
2023-07-11 | Cantor Fitzgerald | Alethia Young | Reiterates | OverweightOverweight | Maintains | - | 3.00 |
Ticker | Company | Chg % | Mkt Cap |
---|---|---|---|
CRIS | Curis | 1836.24% | 866M |
AGLE | Aeglea BioTherapeutics | 0.17% | 46.5M |
GANX | Gain Therapeutics | 18.18% | 47.9M |
CNTB | Connect Biopharma Hldgs | -0.17% | 41M |
VTGN | Vistagen Therapeutics | 0.58% | 48.8M |
You can purchase shares of Curis (NASDAQ: CRIS) through any online brokerage.
Other companies in Curis’s space includes: Aeglea BioTherapeutics (NASDAQ:AGLE), Gain Therapeutics (NASDAQ:GANX), Connect Biopharma Hldgs (NASDAQ:CNTB), Vistagen Therapeutics (NASDAQ:VTGN) and Longeveron (NASDAQ:LGVN).
The latest price target for Curis (NASDAQ: CRIS) was reported by HC Wainwright & Co. on Monday, September 25, 2023. The analyst firm set a price target for 6.00 expecting CRIS to fall to within 12 months (a possible -18.45% downside). 7 analyst firms have reported ratings in the last year.
The stock price for Curis (NASDAQ: CRIS) is $7.3577 last updated Today at September 29, 2023 at 2:32 PM UTC.
There is no dividend information for Curis.
Curis’s Q3 earnings are confirmed for Wednesday, November 8, 2023.
There is no upcoming split for Curis.
Curis is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Curis Stock (NASDAQ: CRIS) stock price, news, charts, stock research, profile.
Open6.000 | Close- |
Vol / Avg.85.796K / 17.185K | Mkt Cap866.035M |
Day Range6.000 - 7.431 | 52 Wk Range7.600 - 20.000 |
Q3 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED) | ||||||
REV |
Q2 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.120 | -0.120 | 0.0000 | ||||
REV | 2.570M | 2.197M | -373.000K |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|---|---|---|---|---|---|---|
2023-09-25 | HC Wainwright & Co. | Edward White | Reiterates | BuyBuy | Maintains | - | 6.00 |
2023-09-07 | Cantor Fitzgerald | Alethia Young | Reiterates | OverweightOverweight | Maintains | - | 3.00 |
2023-08-04 | HC Wainwright & Co. | Edward White | Reiterates | BuyBuy | Maintains | - | 6.00 |
2023-07-11 | Cantor Fitzgerald | Alethia Young | Reiterates | OverweightOverweight | Maintains | - | 3.00 |
Ticker | Company | Chg % | Mkt Cap |
---|---|---|---|
CRIS | Curis | 1836.24% | 866M |
AGLE | Aeglea BioTherapeutics | 0.17% | 46.5M |
GANX | Gain Therapeutics | 18.18% | 47.9M |
CNTB | Connect Biopharma Hldgs | -0.17% | 41M |
VTGN | Vistagen Therapeutics | 0.58% | 48.8M |
You can purchase shares of Curis (NASDAQ: CRIS) through any online brokerage.
Other companies in Curis’s space includes: Aeglea BioTherapeutics (NASDAQ:AGLE), Gain Therapeutics (NASDAQ:GANX), Connect Biopharma Hldgs (NASDAQ:CNTB), Vistagen Therapeutics (NASDAQ:VTGN) and Longeveron (NASDAQ:LGVN).
The latest price target for Curis (NASDAQ: CRIS) was reported by HC Wainwright & Co. on Monday, September 25, 2023. The analyst firm set a price target for 6.00 expecting CRIS to fall to within 12 months (a possible -18.45% downside). 7 analyst firms have reported ratings in the last year.
The stock price for Curis (NASDAQ: CRIS) is $7.3577 last updated Today at September 29, 2023 at 2:32 PM UTC.
There is no dividend information for Curis.
Curis’s Q3 earnings are confirmed for Wednesday, November 8, 2023.
There is no upcoming split for Curis.
Curis is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Curis Stock (NASDAQ: CRIS) stock price, news, charts, stock research, profile.
Open6.000 | Close- |
Vol / Avg.85.796K / 17.185K | Mkt Cap866.035M |
Day Range6.000 - 7.431 | 52 Wk Range7.600 - 20.000 |
Q3 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED) | ||||||
REV |
Q2 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.120 | -0.120 | 0.0000 | ||||
REV | 2.570M | 2.197M | -373.000K |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|---|---|---|---|---|---|---|
2023-09-25 | HC Wainwright & Co. | Edward White | Reiterates | BuyBuy | Maintains | - | 6.00 |
2023-09-07 | Cantor Fitzgerald | Alethia Young | Reiterates | OverweightOverweight | Maintains | - | 3.00 |
2023-08-04 | HC Wainwright & Co. | Edward White | Reiterates | BuyBuy | Maintains | - | 6.00 |
2023-07-11 | Cantor Fitzgerald | Alethia Young | Reiterates | OverweightOverweight | Maintains | - | 3.00 |
Ticker | Company | Chg % | Mkt Cap |
---|---|---|---|
CRIS | Curis | 1836.24% | 866M |
AGLE | Aeglea BioTherapeutics | 0.17% | 46.5M |
GANX | Gain Therapeutics | 18.18% | 47.9M |
CNTB | Connect Biopharma Hldgs | -0.17% | 41M |
VTGN | Vistagen Therapeutics | 0.58% | 48.8M |
You can purchase shares of Curis (NASDAQ: CRIS) through any online brokerage.
Other companies in Curis’s space includes: Aeglea BioTherapeutics (NASDAQ:AGLE), Gain Therapeutics (NASDAQ:GANX), Connect Biopharma Hldgs (NASDAQ:CNTB), Vistagen Therapeutics (NASDAQ:VTGN) and Longeveron (NASDAQ:LGVN).
The latest price target for Curis (NASDAQ: CRIS) was reported by HC Wainwright & Co. on Monday, September 25, 2023. The analyst firm set a price target for 6.00 expecting CRIS to fall to within 12 months (a possible -18.45% downside). 7 analyst firms have reported ratings in the last year.
The stock price for Curis (NASDAQ: CRIS) is $7.3577 last updated Today at September 29, 2023 at 2:32 PM UTC.
There is no dividend information for Curis.
Curis’s Q3 earnings are confirmed for Wednesday, November 8, 2023.
There is no upcoming split for Curis.
Curis is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Curis Stock (NASDAQ: CRIS) stock price, news, charts, stock research, profile.
Open6.000 | Close- |
Vol / Avg.85.796K / 17.185K | Mkt Cap866.035M |
Day Range6.000 - 7.431 | 52 Wk Range7.600 - 20.000 |
Q3 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED) | ||||||
REV |
Q2 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.120 | -0.120 | 0.0000 | ||||
REV | 2.570M | 2.197M | -373.000K |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|---|---|---|---|---|---|---|
2023-09-25 | HC Wainwright & Co. | Edward White | Reiterates | BuyBuy | Maintains | - | 6.00 |
2023-09-07 | Cantor Fitzgerald | Alethia Young | Reiterates | OverweightOverweight | Maintains | - | 3.00 |
2023-08-04 | HC Wainwright & Co. | Edward White | Reiterates | BuyBuy | Maintains | - | 6.00 |
2023-07-11 | Cantor Fitzgerald | Alethia Young | Reiterates | OverweightOverweight | Maintains | - | 3.00 |
Ticker | Company | Chg % | Mkt Cap |
---|---|---|---|
CRIS | Curis | 1836.24% | 866M |
AGLE | Aeglea BioTherapeutics | 0.17% | 46.5M |
GANX | Gain Therapeutics | 18.18% | 47.9M |
CNTB | Connect Biopharma Hldgs | -0.17% | 41M |
VTGN | Vistagen Therapeutics | 0.58% | 48.8M |
You can purchase shares of Curis (NASDAQ: CRIS) through any online brokerage.
Other companies in Curis’s space includes: Aeglea BioTherapeutics (NASDAQ:AGLE), Gain Therapeutics (NASDAQ:GANX), Connect Biopharma Hldgs (NASDAQ:CNTB), Vistagen Therapeutics (NASDAQ:VTGN) and Longeveron (NASDAQ:LGVN).
The latest price target for Curis (NASDAQ: CRIS) was reported by HC Wainwright & Co. on Monday, September 25, 2023. The analyst firm set a price target for 6.00 expecting CRIS to fall to within 12 months (a possible -18.45% downside). 7 analyst firms have reported ratings in the last year.
The stock price for Curis (NASDAQ: CRIS) is $7.3577 last updated Today at September 29, 2023 at 2:32 PM UTC.
There is no dividend information for Curis.
Curis’s Q3 earnings are confirmed for Wednesday, November 8, 2023.
There is no upcoming split for Curis.
Curis is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Curis Stock (NASDAQ: CRIS) stock price, news, charts, stock research, profile.
Open6.000 | Close- |
Vol / Avg.85.796K / 17.185K | Mkt Cap866.035M |
Day Range6.000 - 7.431 | 52 Wk Range7.600 - 20.000 |
Q3 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED) | ||||||
REV |
Q2 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.120 | -0.120 | 0.0000 | ||||
REV | 2.570M | 2.197M | -373.000K |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|---|---|---|---|---|---|---|
2023-09-25 | HC Wainwright & Co. | Edward White | Reiterates | BuyBuy | Maintains | - | 6.00 |
2023-09-07 | Cantor Fitzgerald | Alethia Young | Reiterates | OverweightOverweight | Maintains | - | 3.00 |
2023-08-04 | HC Wainwright & Co. | Edward White | Reiterates | BuyBuy | Maintains | - | 6.00 |
2023-07-11 | Cantor Fitzgerald | Alethia Young | Reiterates | OverweightOverweight | Maintains | - | 3.00 |
Ticker | Company | Chg % | Mkt Cap |
---|---|---|---|
CRIS | Curis | 1836.24% | 866M |
AGLE | Aeglea BioTherapeutics | 0.17% | 46.5M |
GANX | Gain Therapeutics | 18.18% | 47.9M |
CNTB | Connect Biopharma Hldgs | -0.17% | 41M |
VTGN | Vistagen Therapeutics | 0.58% | 48.8M |
You can purchase shares of Curis (NASDAQ: CRIS) through any online brokerage.
Other companies in Curis’s space includes: Aeglea BioTherapeutics (NASDAQ:AGLE), Gain Therapeutics (NASDAQ:GANX), Connect Biopharma Hldgs (NASDAQ:CNTB), Vistagen Therapeutics (NASDAQ:VTGN) and Longeveron (NASDAQ:LGVN).
The latest price target for Curis (NASDAQ: CRIS) was reported by HC Wainwright & Co. on Monday, September 25, 2023. The analyst firm set a price target for 6.00 expecting CRIS to fall to within 12 months (a possible -18.45% downside). 7 analyst firms have reported ratings in the last year.
The stock price for Curis (NASDAQ: CRIS) is $7.3577 last updated Today at September 29, 2023 at 2:32 PM UTC.
There is no dividend information for Curis.
Curis’s Q3 earnings are confirmed for Wednesday, November 8, 2023.
There is no upcoming split for Curis.
Curis is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Curis Stock (NASDAQ: CRIS) stock price, news, charts, stock research, profile.
Open6.000 | Close- |
Vol / Avg.85.796K / 17.185K | Mkt Cap866.035M |
Day Range6.000 - 7.431 | 52 Wk Range7.600 - 20.000 |
Q3 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED) | ||||||
REV |
Q2 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.120 | -0.120 | 0.0000 | ||||
REV | 2.570M | 2.197M | -373.000K |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|---|---|---|---|---|---|---|
2023-09-25 | HC Wainwright & Co. | Edward White | Reiterates | BuyBuy | Maintains | - | 6.00 |
2023-09-07 | Cantor Fitzgerald | Alethia Young | Reiterates | OverweightOverweight | Maintains | - | 3.00 |
2023-08-04 | HC Wainwright & Co. | Edward White | Reiterates | BuyBuy | Maintains | - | 6.00 |
2023-07-11 | Cantor Fitzgerald | Alethia Young | Reiterates | OverweightOverweight | Maintains | - | 3.00 |
Ticker | Company | Chg % | Mkt Cap |
---|---|---|---|
CRIS | Curis | 1836.24% | 866M |
AGLE | Aeglea BioTherapeutics | 0.17% | 46.5M |
GANX | Gain Therapeutics | 18.18% | 47.9M |
CNTB | Connect Biopharma Hldgs | -0.17% | 41M |
VTGN | Vistagen Therapeutics | 0.58% | 48.8M |
You can purchase shares of Curis (NASDAQ: CRIS) through any online brokerage.
Other companies in Curis’s space includes: Aeglea BioTherapeutics (NASDAQ:AGLE), Gain Therapeutics (NASDAQ:GANX), Connect Biopharma Hldgs (NASDAQ:CNTB), Vistagen Therapeutics (NASDAQ:VTGN) and Longeveron (NASDAQ:LGVN).
The latest price target for Curis (NASDAQ: CRIS) was reported by HC Wainwright & Co. on Monday, September 25, 2023. The analyst firm set a price target for 6.00 expecting CRIS to fall to within 12 months (a possible -18.45% downside). 7 analyst firms have reported ratings in the last year.
The stock price for Curis (NASDAQ: CRIS) is $7.3577 last updated Today at September 29, 2023 at 2:32 PM UTC.
There is no dividend information for Curis.
Curis’s Q3 earnings are confirmed for Wednesday, November 8, 2023.
There is no upcoming split for Curis.
Curis is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Curis Stock (NASDAQ: CRIS) stock price, news, charts, stock research, profile.
Open6.000 | Close- |
Vol / Avg.85.796K / 17.185K | Mkt Cap866.035M |
Day Range6.000 - 7.431 | 52 Wk Range7.600 - 20.000 |
Q3 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED) | ||||||
REV |
Q2 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.120 | -0.120 | 0.0000 | ||||
REV | 2.570M | 2.197M | -373.000K |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|---|---|---|---|---|---|---|
2023-09-25 | HC Wainwright & Co. | Edward White | Reiterates | BuyBuy | Maintains | - | 6.00 |
2023-09-07 | Cantor Fitzgerald | Alethia Young | Reiterates | OverweightOverweight | Maintains | - | 3.00 |
2023-08-04 | HC Wainwright & Co. | Edward White | Reiterates | BuyBuy | Maintains | - | 6.00 |
2023-07-11 | Cantor Fitzgerald | Alethia Young | Reiterates | OverweightOverweight | Maintains | - | 3.00 |
Ticker | Company | Chg % | Mkt Cap |
---|---|---|---|
CRIS | Curis | 1836.24% | 866M |
AGLE | Aeglea BioTherapeutics | 0.17% | 46.5M |
GANX | Gain Therapeutics | 18.18% | 47.9M |
CNTB | Connect Biopharma Hldgs | -0.17% | 41M |
VTGN | Vistagen Therapeutics | 0.58% | 48.8M |
You can purchase shares of Curis (NASDAQ: CRIS) through any online brokerage.
Other companies in Curis’s space includes: Aeglea BioTherapeutics (NASDAQ:AGLE), Gain Therapeutics (NASDAQ:GANX), Connect Biopharma Hldgs (NASDAQ:CNTB), Vistagen Therapeutics (NASDAQ:VTGN) and Longeveron (NASDAQ:LGVN).
The latest price target for Curis (NASDAQ: CRIS) was reported by HC Wainwright & Co. on Monday, September 25, 2023. The analyst firm set a price target for 6.00 expecting CRIS to fall to within 12 months (a possible -18.45% downside). 7 analyst firms have reported ratings in the last year.
The stock price for Curis (NASDAQ: CRIS) is $7.3577 last updated Today at September 29, 2023 at 2:32 PM UTC.
There is no dividend information for Curis.
Curis’s Q3 earnings are confirmed for Wednesday, November 8, 2023.
There is no upcoming split for Curis.
Curis is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Curis Stock (NASDAQ: CRIS) stock price, news, charts, stock research, profile.
Open6.000 | Close- |
Vol / Avg.85.796K / 17.185K | Mkt Cap866.035M |
Day Range6.000 - 7.431 | 52 Wk Range7.600 - 20.000 |
Q3 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED) | ||||||
REV |
Q2 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.120 | -0.120 | 0.0000 | ||||
REV | 2.570M | 2.197M | -373.000K |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|---|---|---|---|---|---|---|
2023-09-25 | HC Wainwright & Co. | Edward White | Reiterates | BuyBuy | Maintains | - | 6.00 |
2023-09-07 | Cantor Fitzgerald | Alethia Young | Reiterates | OverweightOverweight | Maintains | - | 3.00 |
2023-08-04 | HC Wainwright & Co. | Edward White | Reiterates | BuyBuy | Maintains | - | 6.00 |
2023-07-11 | Cantor Fitzgerald | Alethia Young | Reiterates | OverweightOverweight | Maintains | - | 3.00 |
Ticker | Company | Chg % | Mkt Cap |
---|---|---|---|
CRIS | Curis | 1836.24% | 866M |
AGLE | Aeglea BioTherapeutics | 0.17% | 46.5M |
GANX | Gain Therapeutics | 18.18% | 47.9M |
CNTB | Connect Biopharma Hldgs | -0.17% | 41M |
VTGN | Vistagen Therapeutics | 0.58% | 48.8M |
You can purchase shares of Curis (NASDAQ: CRIS) through any online brokerage.
Other companies in Curis’s space includes: Aeglea BioTherapeutics (NASDAQ:AGLE), Gain Therapeutics (NASDAQ:GANX), Connect Biopharma Hldgs (NASDAQ:CNTB), Vistagen Therapeutics (NASDAQ:VTGN) and Longeveron (NASDAQ:LGVN).
The latest price target for Curis (NASDAQ: CRIS) was reported by HC Wainwright & Co. on Monday, September 25, 2023. The analyst firm set a price target for 6.00 expecting CRIS to fall to within 12 months (a possible -18.45% downside). 7 analyst firms have reported ratings in the last year.
The stock price for Curis (NASDAQ: CRIS) is $7.3577 last updated Today at September 29, 2023 at 2:32 PM UTC.
There is no dividend information for Curis.
Curis’s Q3 earnings are confirmed for Wednesday, November 8, 2023.
There is no upcoming split for Curis.
Curis is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Curis Stock (NASDAQ: CRIS) stock price, news, charts, stock research, profile.
Open6.000 | Close- |
Vol / Avg.85.796K / 17.185K | Mkt Cap866.035M |
Day Range6.000 - 7.431 | 52 Wk Range7.600 - 20.000 |
Q3 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED) | ||||||
REV |
Q2 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.120 | -0.120 | 0.0000 | ||||
REV | 2.570M | 2.197M | -373.000K |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|---|---|---|---|---|---|---|
2023-09-25 | HC Wainwright & Co. | Edward White | Reiterates | BuyBuy | Maintains | - | 6.00 |
2023-09-07 | Cantor Fitzgerald | Alethia Young | Reiterates | OverweightOverweight | Maintains | - | 3.00 |
2023-08-04 | HC Wainwright & Co. | Edward White | Reiterates | BuyBuy | Maintains | - | 6.00 |
2023-07-11 | Cantor Fitzgerald | Alethia Young | Reiterates | OverweightOverweight | Maintains | - | 3.00 |
Ticker | Company | Chg % | Mkt Cap |
---|---|---|---|
CRIS | Curis | 1836.24% | 866M |
AGLE | Aeglea BioTherapeutics | 0.17% | 46.5M |
GANX | Gain Therapeutics | 18.18% | 47.9M |
CNTB | Connect Biopharma Hldgs | -0.17% | 41M |
VTGN | Vistagen Therapeutics | 0.58% | 48.8M |
You can purchase shares of Curis (NASDAQ: CRIS) through any online brokerage.
Other companies in Curis’s space includes: Aeglea BioTherapeutics (NASDAQ:AGLE), Gain Therapeutics (NASDAQ:GANX), Connect Biopharma Hldgs (NASDAQ:CNTB), Vistagen Therapeutics (NASDAQ:VTGN) and Longeveron (NASDAQ:LGVN).
The latest price target for Curis (NASDAQ: CRIS) was reported by HC Wainwright & Co. on Monday, September 25, 2023. The analyst firm set a price target for 6.00 expecting CRIS to fall to within 12 months (a possible -18.45% downside). 7 analyst firms have reported ratings in the last year.
The stock price for Curis (NASDAQ: CRIS) is $7.3577 last updated Today at September 29, 2023 at 2:32 PM UTC.
There is no dividend information for Curis.
Curis’s Q3 earnings are confirmed for Wednesday, November 8, 2023.
There is no upcoming split for Curis.
Curis is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.